Background and Purpose-To identify the specific post-endovascular stroke therapy (EVT) peak systolic blood pressure(SBP) threshold that best discriminates good from bad functional outcomes (a priori hypothesized to be 160 mm Hg), weconducted a prospective, multicenter, cohort study with a prespecified analysis plan.Methods-Consecutive adult patients treated with EVT for an anterior ischemic stroke were enrolled from November 2017to July 2018 at 12 comprehensive stroke centers accross the United States. All SBP values within 24 hours post-EVTwere recorded. Using Youden index, the threshold of peak SBP that best discriminated primary outcome of dichotomized90-day modified Rankin Scale score (0-2 versus 3-6) was identified. Association of this SBP threshold with the outcomeswas quantified using multiple logistic regression.Results-Among 485 enrolled patients (median age, 69 [interquartile range, 57-79] years; 51% females), a peak SBPof 158 mm Hg was associated with the largest difference in the dichotomous modified Rankin Scale score (absoluterisk reduction of 19%). Having a peak SBP >158 mm Hg resulted in an increased likelihood of modified Rankin Scalescore 3 to 6 (odds ratio, 2.24 [1.52-3.29], P<0.01; adjusted odds ratio, 1.29 [0.81-2.06], P=0.28, after adjustment forprespecified variables).Conclusions-A peak post-EVT SBP of 158 mmHg was prospectively identified to best discriminate good from badfunctional outcome. Those with a peak SBP >158 had an increased likelihood of having a bad outcome in unadjusted, butnot in adjusted analysis. The observed effect size was similar to prior studies. This finding should undergo further testingin a future randomized trial of goal-targeted post-EVT antihypertensive treatment.
Bibliographical noteFunding Information:
This study was supported by the Society of Vascular and Interventional Neurology, University of Cincinnati Gardner Neuroscience Institute, National Institutes of Health/National Institute of Neurological Disorders and Stroke (U01 NS086872 and U10 NS086512), and National Center for Advancing Translational Sciences/Clinical and Translational Science Awards Program (UL1 TR002243).
© 2019 American Heart Association, Inc.
- Antihypertensive agents
- Blood pressure
- Brain ischemia
- Retrospective studies